Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Marshall Wace LLP

Marshall Wace LLP increased its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 4,422.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 456,762 shares of the biotechnology company's stock after buying an additional 446,662 shares during the period. Marshall Wace LLP owned 0.50% of Rocket Pharmaceuticals worth $5,741,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Walleye Capital LLC raised its stake in shares of Rocket Pharmaceuticals by 59.1% during the fourth quarter. Walleye Capital LLC now owns 220,142 shares of the biotechnology company's stock valued at $2,767,000 after acquiring an additional 81,739 shares in the last quarter. XTX Topco Ltd raised its position in Rocket Pharmaceuticals by 310.5% during the 4th quarter. XTX Topco Ltd now owns 63,634 shares of the biotechnology company's stock valued at $800,000 after purchasing an additional 48,131 shares in the last quarter. Mariner LLC purchased a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth $139,000. Synovus Financial Corp grew its position in shares of Rocket Pharmaceuticals by 71.6% during the 4th quarter. Synovus Financial Corp now owns 163,893 shares of the biotechnology company's stock worth $2,060,000 after buying an additional 68,389 shares in the last quarter. Finally, Covestor Ltd increased its stake in shares of Rocket Pharmaceuticals by 33,166.7% during the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after buying an additional 1,990 shares during the period. 98.39% of the stock is owned by hedge funds and other institutional investors.

Rocket Pharmaceuticals Stock Performance

NASDAQ:RCKT traded down $0.20 during trading hours on Friday, hitting $7.23. 1,634,069 shares of the company were exchanged, compared to its average volume of 1,328,421. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals, Inc. has a 52-week low of $4.55 and a 52-week high of $26.98. The stock has a market capitalization of $770.93 million, a price-to-earnings ratio of -2.63 and a beta of 1.00. The company's 50 day moving average price is $7.64 and its 200-day moving average price is $11.36.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. As a group, research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Insider Activity

In other Rocket Pharmaceuticals news, insider Kinnari Patel bought 21,099 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $99,165.30. Following the completion of the transaction, the insider now directly owns 26,774 shares of the company's stock, valued at approximately $125,837.80. This trade represents a 371.79 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Aaron Ondrey sold 7,489 shares of the stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.81. Following the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. This represents a 5.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 28.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an "outperform" rating and a $32.00 price objective for the company. Scotiabank increased their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. The Goldman Sachs Group lowered their target price on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and issued a $42.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 9th. Finally, BMO Capital Markets assumed coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price objective for the company. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $43.00.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.